Epitope alteration by small molecules and applications in drug discovery.
Ontology highlight
ABSTRACT: Small molecules and antibodies are normally considered separately in drug discovery, except in the case of covalent conjugates. We unexpectedly discovered several small molecules that could inhibit or enhance antibody-epitope interactions which opens new possibilities in drug discovery and therapeutic modulation of auto-antibodies. We first discovered a small molecule, CRANAD-17, that enhanced the binding of an antibody to amyloid beta (Aβ), one of the major hallmarks of Alzheimer's disease, by stable triplex formation. Next, we found several small molecules that altered antibody-epitope interactions of tau and PD-L1 proteins, demonstrating the generality of this phenomenon. We report a new screening technology for ligand discovery, screening platform based on epitope alteration for drug d
SUBMITTER: Zhu B
PROVIDER: S-EPMC9278120 | biostudies-literature | 2022 Jul
REPOSITORIES: biostudies-literature
ACCESS DATA